Vertex Pharmaceuticals Incorporated
VRTX
$462.13
$5.261.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.88% | 11.66% | 10.06% | 8.76% | 10.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.98% | 11.66% | 10.06% | 8.76% | 10.61% |
| Cost of Revenue | 14.50% | 12.90% | 17.14% | 19.32% | 20.61% |
| Gross Profit | 4.53% | 10.66% | 4.60% | 1.03% | 3.68% |
| SG&A Expenses | 19.96% | 25.96% | 40.67% | 32.41% | 27.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.67% | 15.57% | 21.78% | 21.97% | 22.04% |
| Operating Income | 0.18% | 6.62% | -3.87% | -6.11% | -1.52% |
| Income Before Tax | -106.30% | -94.33% | -93.98% | -95.01% | 14.35% |
| Income Tax Expenses | -7.93% | 3.14% | -11.90% | -25.15% | -17.75% |
| Earnings from Continuing Operations | -124.60% | -114.80% | -113.83% | -114.56% | 23.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -124.60% | -114.80% | -113.83% | -114.56% | 23.31% |
| EBIT | 0.18% | 6.62% | -3.87% | -6.11% | -1.52% |
| EBITDA | 0.02% | 6.65% | -2.70% | -5.01% | -0.75% |
| EPS Basic | -124.45% | -114.72% | -113.76% | -114.46% | 22.70% |
| Normalized Basic EPS | -1.96% | 4.80% | -1.35% | -0.73% | 5.91% |
| EPS Diluted | -125.47% | -115.87% | -114.98% | -115.73% | 22.77% |
| Normalized Diluted EPS | -1.74% | 5.00% | -1.14% | -0.44% | 5.99% |
| Average Basic Shares Outstanding | -0.11% | 0.10% | 0.19% | 0.34% | 0.48% |
| Average Diluted Shares Outstanding | -0.37% | -0.14% | -0.05% | 0.02% | 0.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |